Alain Didier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alain Didier has a total of 869 co-authors. Here are the top co-authors by number of shared publications:
- Pascal Demoly
University Hospital of Montpellier
6 shared publications - Ludger Klimek
Department of Otolaryngology, Head and Neck Surgery Universitätsmedizin Mainz Mainz Germany
5 shared publications - Aziz Sheikh
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
4 shared publications - Cezmi A. Akdis
Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich Davos Switzerland
4 shared publications Gilles Devouassoux
CRISALIS/F-CRIN INSERM Network, Toulouse, France
4 shared publications- Giorgio Walter Canonica
Personalized Medicine, Asthma and Allergy Humanitas Clinical & Research Center, IRCCS Rozzano Italy
4 shared publications
Latest Publications
- 24 September 2026
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 66 (5)
Quoi de neuf en allergologie… ? Faire le tri dans une littérature toujours plus abondante
- 24 September 2026
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 66 (5)
Quoi de neuf en allergologie… ? Faire le tri dans une littérature toujours plus abondante
- 16 June 2026
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 66 (4)
Nouvelles recommandations pour la prévention de l’asthme et de l’allergie : l’EAACI se met au vert !
- 16 June 2026
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 66 (4)
Nouvelles recommandations pour la prévention de l’asthme et de l’allergie : l’EAACI se met au vert !
- Open Access
Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial
Background: Tablet formulations of allergen extracts are widely recommended over other formulations for the sublingual immunotherapy (SLIT) of respiratory allergies. However, with adequate clinical trial evidence, SLIT (liquid) drop formulations may be a relevant allergy treatment option. Methods: The RHAPSODY multinational, Phase III, parallel‐group, double‐blind, placebo‐controlled, randomised clinical study of adults with moderate‐to‐severe, grass‐pollen‐induced allergic rhinoconjunctivitis (ARC) with or without asthma was conducted at 45 investigating centres in six European countries. Participants received 26 months of continuous treatment with active 5‐grass‐pollen SLIT drops or placebo. The primary efficacy endpoint was the average daily total combined score (TCS, comprising a symptom score and a rescue medication score) during the second peak grass pollen season (PGPS). Results: Of the 445 randomised patients (mean ± standard deviation (range) age: 32.6 ± 9.9 (18–63); males: 55.1%), 389 completed the trial. The primary efficacy endpoint showed a statistically significant difference in favour of active treatment versus placebo (average difference in the daily TCS: 1.88 (95% CI: 0.60–3.17); relative difference 26.51% (95% CI: 9.42–40.55); p = 0.0036). The difference (0.17 points) in the average weekly Rhinitis Quality of Life Questionnaire score during the second PGPS in favour of the active treatment was clinically relevant but not statistically significant. The differences in efficacy were generally driven by the medication score, rather than the symptom score. Most adverse events were mild and local. Conclusions: RHAPSODY was the first well‐powered clinical trial to show the positive risk–benefit ratio of 5‐grass‐pollen SLIT drops in adult participants with moderate‐to‐severe grass‐pollen‐induced ARC.
Open AccessFive‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial
Background: Tablet formulations of allergen extracts are widely recommended over other formulations for the sublingual immunotherapy (SLIT) of respiratory allergies. However, with adequate clinical trial evidence, SLIT (liquid) drop formulations may be a relevant allergy treatment option. Methods: The RHAPSODY multinational, Phase III, parallel‐group, double‐blind, placebo‐controlled, randomised clinical study of adults with moderate‐to‐severe, grass‐pollen‐induced allergic rhinoconjunctivitis (ARC) with or without asthma was conducted at 45 investigating centres in six European countries. Participants received 26 months of continuous treatment with active 5‐grass‐pollen SLIT drops or placebo. The primary efficacy endpoint was the average daily total combined score (TCS, comprising a symptom score and a rescue medication score) during the second peak grass pollen season (PGPS). Results: Of the 445 randomised patients (mean ± standard deviation (range) age: 32.6 ± 9.9 (18–63); males: 55.1%), 389 completed the trial. The primary efficacy endpoint showed a statistically significant difference in favour of active treatment versus placebo (average difference in the daily TCS: 1.88 (95% CI: 0.60–3.17); relative difference 26.51% (95% CI: 9.42–40.55); p = 0.0036). The difference (0.17 points) in the average weekly Rhinitis Quality of Life Questionnaire score during the second PGPS in favour of the active treatment was clinically relevant but not statistically significant. The differences in efficacy were generally driven by the medication score, rather than the symptom score. Most adverse events were mild and local. Conclusions: RHAPSODY was the first well‐powered clinical trial to show the positive risk–benefit ratio of 5‐grass‐pollen SLIT drops in adult participants with moderate‐to‐severe grass‐pollen‐induced ARC.
- 24 July 2025
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 42 (8) , 387-393
Venues aux urgences pour asthme et devenir à l’issue : enquête PASS du réseau CRISALIS
- 24 July 2025
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 42 (8) , 387-393
Venues aux urgences pour asthme et devenir à l’issue : enquête PASS du réseau CRISALIS
- 26 April 2023
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 207 (5) , 612-618
Quelle biothérapie choisir en fonction des caractéristiques de l’asthme sévère chez l’adulte ?
- 26 April 2023
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 207 (5) , 612-618
Quelle biothérapie choisir en fonction des caractéristiques de l’asthme sévère chez l’adulte ?
- Top Cited PapersOpen Access
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.
Top Cited PapersOpen AccessRhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 17
Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
Background: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. Purpose: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. Design: The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. Methods: Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. Results: The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. Conclusion: Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 17
Open AccessImprovement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
Background: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. Purpose: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. Design: The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. Methods: Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. Results: The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. Conclusion: Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.
- 3 October 2022
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part B
- Vol. 25 (7) , 372-392
Idiopathic Pulmonary Fibrosis: What do we Know about the Role of Occupational and Environmental Determinants? A Systematic Literature Review and Meta-Analysis
The objectives of this systematic review of original articles published up until August 2021 and meta-analyses were to identify the links between occupational and non-occupational environmental exposures, types of occupations and idiopathic pulmonary fibrosis (IPF). Sixteen selected case-control studies were qualified as good level with Newcastle-Ottawa quality assessment scale. Sensitivity analyses highlighted the role of choice of control group, tobacco adjustment and diagnostic tools. Significantly increased risks of IPF were observed (OR (95%CI): for metals (1.42(1.05–1.92)), wood (OR:1.32(1.02–1.71)), and general dust (OR:1.32(1.08–1.63)) exposures. Subgroup analyses found a significantly elevated risk for: hardwood (OR:1.75 (1.13–2.70)), organic dusts (OR:1.72 (1.20–2.46)) and pesticides (OR:2.30 (1.30–4.08)), while no significant change was noted for softwoods and solvents. Smoking adjustments: general dust (1.45 (1.04–2.03)/organic dust (2.5 (1.49–4.22)/metals (1.87 (1.16–3)/wood dust OR: 1.16 (0.86–1.61)/pesticide exposure 2.4 (0.84–6.9) were calculated. Among agricultural workers, the risk was also increased (OR:2.06 (1.02–4.16)). Few environmental data were available and no significant associations detected. Thus, these meta-analyses highlighted the role of some occupational exposures in IPF occurrence. A more accurate and thorough assessment of exposures over the entire working life as well as on the duration and intensity of exposure and complex of multi-pollutant exposure is needed in future research and clinical practice. Graphical Abstract
- 3 October 2022
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part B
- Vol. 25 (7) , 372-392
Idiopathic Pulmonary Fibrosis: What do we Know about the Role of Occupational and Environmental Determinants? A Systematic Literature Review and Meta-Analysis
The objectives of this systematic review of original articles published up until August 2021 and meta-analyses were to identify the links between occupational and non-occupational environmental exposures, types of occupations and idiopathic pulmonary fibrosis (IPF). Sixteen selected case-control studies were qualified as good level with Newcastle-Ottawa quality assessment scale. Sensitivity analyses highlighted the role of choice of control group, tobacco adjustment and diagnostic tools. Significantly increased risks of IPF were observed (OR (95%CI): for metals (1.42(1.05–1.92)), wood (OR:1.32(1.02–1.71)), and general dust (OR:1.32(1.08–1.63)) exposures. Subgroup analyses found a significantly elevated risk for: hardwood (OR:1.75 (1.13–2.70)), organic dusts (OR:1.72 (1.20–2.46)) and pesticides (OR:2.30 (1.30–4.08)), while no significant change was noted for softwoods and solvents. Smoking adjustments: general dust (1.45 (1.04–2.03)/organic dust (2.5 (1.49–4.22)/metals (1.87 (1.16–3)/wood dust OR: 1.16 (0.86–1.61)/pesticide exposure 2.4 (0.84–6.9) were calculated. Among agricultural workers, the risk was also increased (OR:2.06 (1.02–4.16)). Few environmental data were available and no significant associations detected. Thus, these meta-analyses highlighted the role of some occupational exposures in IPF occurrence. A more accurate and thorough assessment of exposures over the entire working life as well as on the duration and intensity of exposure and complex of multi-pollutant exposure is needed in future research and clinical practice. Graphical Abstract
- 28 September 2022
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 83, 100956
Reply to Gille and collaborators: DM and VC impairment after COVID-1
- 28 September 2022
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 83, 100956
Reply to Gille and collaborators: DM and VC impairment after COVID-1
- Open Access
- 15 June 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2066424
Update about Oralair® as a treatment for grass pollen allergic rhinitis
Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3–5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.
- 15 June 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2066424
Open AccessUpdate about Oralair® as a treatment for grass pollen allergic rhinitis
Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3–5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.